CanaDan Bio ApS: Financial statements 2022
CVR: 40896813
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
CanaDan Bio ApS (CVR 40896813) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -2,659 and a net result of DKK 6,169 compared with DKK -10,711 the year before. Equity in the 2022 report amounted to DKK 11,453. The solvency ratio was 1.7%.
- Revenue
- DKK 0
- Gross Profit
- DKK -2,659
- Profit/Loss
- DKK 6,169
- Equity
- DKK 11,453
- Total Assets
- DKK 676,046
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | 0 | -3K | 6K | 11K | - |
| 2021 | 0 | -47K | -11K | 5K | - |
| 2020 | 0 | -23K | -24K | 16K | - |
Official annual report
Keep an eye on CanaDan Bio ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
CanaDan Bio ApS has published its annual report for 2021. Revenue came to DKK 0, and the net result was DKK -10,711.
About CanaDan Bio ApS
CanaDan Bio ApS is a Danish company of the type Anpartsselskab based in Vanløse, founded in 2019. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Lionel le Lay. The company is owned by PYTHOR ApS and Megapol ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -1,395 and a net result of DKK 4,372 compared with DKK 3,483 the year before. Equity in the 2025 report amounted to DKK 28,083.